The University of Wisconsin School of Medicine and Public Health is recruiting participants for a Phase 3 trial that will test the efficacy and safety of lecanemab (BAN2401) in those who are at risk of developing symptoms of Alzheimer’s disease. The global AHEAD (NCT04468659) study seeks to enroll 1,165 participants in North America to test lecanemab in a larger group of people, after encouraging data in previous Phase 1 and 2 trials. Recommended Reading April 22, 2021…
You must be logged in to read/download the full post.
The post Phase 3 Trial of Lecanemab Seeks People At Risk of Alzheimer’s appeared first on BioNewsFeeds.